Clinical trials: Castration-Resistant Prostate Carcinoma
Prostate Cancer
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of prostate cancer.
- Trial name
- NCT00025116
- Testing
- gefitinib
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Cancer
TKI258 in Castrate Resistant Prostate Cancer
The goal of this clinical research study is to learn if a decrease in the levels of prostate specific antigen (PSA) may be linked with the status of prostate cancer that has spread to the bones.
- Trial name
- NCT00831792
- Testing
- TK1258
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumors
TT-702 in Patients With Advanced Solid Tumours.
This clinical trial is evaluating the drug candidate TT-702 in patients with advanced solid tumours. The main aims of the trial are to determine the maximum dose of TT-702 that can be given safely to patients alone and in…
- Trial name
- CURATE (NCT05272709)
- Testing
- TT-702, Anti-PD-1 and PD-L1 agent
- Where
- 3 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Cancer Research UK
Metastatic Castration-resistant Prostate Cancer
Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer
The death of prostate cancer patients is mainly due to metastatic castration-resistant prostate cancer. Though some new therapies has been tried to prolong the life-span of mCRPC patients, a dilemma was encountered for the…
- Trial name
- NCT04225910
- Testing
- 225Ac-PSMA
- Volunteers
- 20 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Prostate Cancer
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole
This research trial studies biomarkers in bone marrow and blood samples from patients with prostate cancer treated with ketoconazole.
- Trial name
- NCT01275651
- Testing
- laboratory biomarker analysis
- Where
- United States
- Sponsor
- Alliance for Clinical Trials in Oncology
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Saracatinib in Treating Patients With Prostate Cancer
This randomized phase II clinical trial is studying how well saracatinib works in treating patients with prostate cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01267266
- Testing
- saracatinib
- Where
- 15 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
This phase II trial tests how well vorinostat works in treating patients with prostate-specific membrane antigen (PSMA)-low castration-resistant prostate cancer that has spread from where it first started (primary site) to other…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT06145633
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Scan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fred Hutchinson Cancer Center
Prostatic Neoplasms, Castration-Resistant
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
This study is a Japanese post-marketing surveillance (PMS) which is required by the regulatory authorities. General objective of PMS is to confirm the clinical usefulness, especially the safety profile of a drug under the routine…
- Trial name
- NCT02803437
- Testing
- Radium-223 dichloride (Xofigo, BAY 88-8223)
- Where
- Japan
- Volunteers
- 334 people
- Sponsor
- Bayer
Castration-resistant Prostate Cancer, Stage IV Prostate Cancer
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
This randomized phase II trial studies the best way to give abiraterone acetate in treating patients with castration-resistant prostate cancer.
- Trial name
- NCT01543776
- Testing
- abiraterone acetate
- Where
- 6 sites in United States, Singapore
- Volunteers
- 72 people
- Sponsor
- University of Chicago
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer
Phase II trial to study the effectiveness of combination chemotherapy plus monoclonal antibody therapy in treating patients who have metastatic prostate cancer that has not responded to previous hormone therapy.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00016107
- Testing
- estramustine phosphate sodium, docetaxel, bevacizumab
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Prostate Cancer
Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC
More than 90% of patients with metastatic castration-resistant prostate cancer (mCRPC) no longer responding to androgen deprivation hormonal therapy have evidence of bone metastases.
- Trial name
- TRANCE (NCT03432949)
- Testing
- Dexamethasone plus Radium-223
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic…
- Trial name
- NCT00003626
- Testing
- dolastatin 10
- Where
- 3 sites in United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy
This trial studies image-guided biopsies work in identifying mechanisms of resistance in participants with castration resistant prostate cancer that has spread to other places in the body and who are undergoing radioligand…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT03596710
- Testing
- Image Guided Biopsy
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than once drug may kill more tumor cells.
- Trial name
- NCT00003717
- Testing
- estramustine phosphate sodium, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- St. Barnabas Medical Center
Prostate Cancer
Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer
RATIONALE: Antiandrogen withdrawal may be an effective treatment for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of ketoconazole and hydrocortisone for antiandrogen withdrawal in treating men…
- Trial name
- NCT00002760
- Testing
- ketoconazole, therapeutic hydrocortisone, Withdrawal of antiandrogen therapy
- Where
- 2 sites in United States
- Volunteers
- 260 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Castrate Resistance Prostate Cancer
Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer
This is a single site, prospective, Phase 1 pilot trial intended to evaluate the safety and tolerability of adding one IV dose of Desmopressin to CRPC subjects at least 30 minutes prior to commencing standard IV Docetaxel…
- Trial name
- NCT04113005
- Testing
- Desmopressin
- Volunteers
- 10 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer
Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with G-CSF may make tumor cells more sensitive to the chemotherapy drug and may kill…
- Trial name
- NCT00003183
- Testing
- filgrastim, mitoxantrone hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Hope Cancer Institute, Inc.
Prostate Cancer
Behavior-Based Dietary Intervention in Treating Patients With Hormone-Refractory Prostate Cancer
RATIONALE: A low-fat, high-fiber diet that includes soy protein may prevent disease progression in patients with hormone-refractory prostate cancer. Nutrition counseling may help motivate patients to follow this diet.
- Trial name
- NCT00082732
- Testing
- behavioral dietary intervention, dietary intervention, therapeutic dietary intervention
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- M.D. Anderson Cancer Center
Castration-resistant Prostate Cancer
Long-Term Specified Drug Use-Results Survey for Xtandi Capsule
The purpose of this study is to confirm the long term safety and efficacy of enzalutamide in patients.
- Trial name
- NCT02669771
- Testing
- enzalutamide
- Where
- 47 sites in Japan
- Volunteers
- 1,018 people
- Sponsor
- Astellas Pharma Inc
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
This phase II trial tests how well re-treatment with 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic), that…
- Trial name
- NCT06288113
- Testing
- Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Jonsson Comprehensive Cancer Center